FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

FTC v. Actavis - Where do Hatch-Waxman settlements go from here?

Speaking Engagement
On June 17, 2013, the Supreme Court decided Federal Trade Commission v. Actavis, Inc., which resolved a circuit split over the appropriate antitrust standard to apply when evaluating "reverse payment" Hatch-Waxman patent litigation settlements. This decision has significant consequences for settlements in branded vs. generic abbreviated new drug application (ANDA) litigation in the pharmaceutical industry.

WilmerHale Partner Mark Ford is a featured speaker at this Boston Bar Association event, and will be presenting an antitrust analysis of reverse payment settlements in Hatch-Waxman cases.

Read More About the Event

Speakers

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link. (The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.